Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Prevalence of Subclinical Atherosclerosis and Its Associated Factors in Hyperlipidemic Korean Adults With Diabetes (ALTO)

This study has been completed.
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: December 17, 2010
Last updated: March 12, 2012
Last verified: March 2012
This study is to investigate correlation between Carotid Intima Media Thickness (cIMT) and several factors such as; hs C-reactive protein (CRP), HbA1c, lipid profile in Korean diabetic patients with atherosclerosis. Total 360 patients will be enrolled through 6 sites.

Diabetes Mellitus

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Prevalence of Subclinical Atherosclerosis and Its Associated Factors in Hyperlipidemic Korean Adults With Diabetes

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Measurement of intima media thickness, visit 1 [ Time Frame: Visit 1 ]
  • Measurement of intima media thickness, visit 2 [ Time Frame: Visit 2 ]

Secondary Outcome Measures:
  • hs-C-Reactive Protein, visit 1 [ Time Frame: Visit 1 ]
  • hs-C-Reactive Protein, visit 2 [ Time Frame: Visit 2 ]

Biospecimen Retention:   Samples Without DNA
Whole blood and serum, urine

Enrollment: 181
Study Start Date: January 2011
Study Completion Date: April 2011
Primary Completion Date: April 2011 (Final data collection date for primary outcome measure)

Detailed Description:

Ages Eligible for Study:   20 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
360 patients who has diabetic mellitus with dyslipidemia

Inclusion Criteria:

  • patients with Diabetic Mellitus
  • patients with dyslipidemia

Exclusion Criteria:

  • patients who have established cardiovascular disease
  • patient using NSAID
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01264263

Korea, Republic of
Research Site
Anyang, Korea, Republic of
Research Site
Koyang, Korea, Republic of
Research Site
Seoul, Korea, Republic of
Sponsors and Collaborators
Study Chair: Dongsun Kim Hanyang University
Principal Investigator: Eunkyung Hong Hallym University Kangnam Sacred Heart Hospital
Principal Investigator: Hyunsang Kwon Yeoido Saint Mary's Hospital
Principal Investigator: Dongjoon Kim Ilsan-Paik Hospital
Principal Investigator: Sungjin Lee Hallym University Hospital
Principal Investigator: Singon Kim Korea University Anam Hospital
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: AstraZeneca Identifier: NCT01264263     History of Changes
Other Study ID Numbers: NIS-CKR-DUM-2010/1
Study First Received: December 17, 2010
Last Updated: March 12, 2012

Keywords provided by AstraZeneca:
hs CRP (C-reactive protein)
DM (Diabetic Mellitus)
Corelation between cIMT (carotid intima media thickness)
Cardio Vascular risk in Diabetic Mellitus

Additional relevant MeSH terms:
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Lipid Metabolism Disorders processed this record on May 22, 2017